Azitra denies report of $44 million securities offering

Azitra Inc. (NYSE American: AZTR) said a report claiming the company priced a $44 million registered direct offering is false and should not be relied upon.

The clinical-stage biopharmaceutical company, based in Branford, Connecticut, announced it became aware of the circulating report and is taking steps to identify its source.

Azitra urged investors, stakeholders and the public to rely only on information formally issued by the company through its official channels.

The company focuses on developing therapies for precision dermatology. Its lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare chronic skin disease with no approved treatment options.

Azitra's ATR-04 program utilizes another engineered strain of S. epidermidis for treating EGFR inhibitor-associated rash, which affects approximately 150,000 people in the United States. The company received Fast Track designation from the FDA for this indication.

The company also is progressing ATR-01, a preclinical program targeting ichthyosis vulgaris, with plans to submit an investigational new drug application in 2026.

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• UBS Upgrades UL Solutions Inc (ULS) to Buy
• Jefferies Starts Buzzi Unicem SpA (BZU:IM) (BZZUY) at Hold